Bloodworks

Bloodworks, doing business as Puget Sound Blood Center And Program, operates as a Seattle-based tax-exempt nonprofit that supplies blood products, blood donor testing services, infectious disease screening, and specialized laboratory testing panels to federal healthcare systems as a prime contractor (94% of recent awards) and as a sub-recipient on NIH-funded research grants. The vendor competes entirely in full-and-open procurement with no set-aside designations across its federal footprint.

Bloodworks' federal customer base is heavily concentrated in the Department of Veterans Affairs and the Department of Defense. The top five funding agencies account for 95% of combined potential value, led by Veterans Integrated Service Network 20 (37 awards, $81.3 million combined potential value), the Department of the Army Medical Command (157 awards, $33.2 million), and the Defense Health Agency (21 awards, $27.7 million). The two rankings diverge meaningfully: while Army Medical Command leads by award count, VISN 20 anchors the dollar value through a small number of large single-award IDIQs, including an $8,999,999 indefinite-delivery contract awarded August 1, 2026, for blood products and comprehensive laboratory testing to Puget Sound VA Medical Center running through July 31, 2031. Representative prime contract work includes a $1,862,500 delivery order from VISN 20 for blood and blood products to Puget Sound VA Medical Center (August 1, 2026, through July 31, 2027), a $4,992,175 single-award IDIQ from the Defense Health Agency for blood donor testing at Madigan Army Medical Center in Lewis McChord, Washington (March 1, 2024, through February 28, 2029), and a $625,000 single-award IDIQ from VISN 20 for renal testing services at Portland VA Medical Center (September 30, 2024, through September 29, 2029).

The vendor holds positions on five named parent vehicles: a Blanket Purchase Agreement (W91YU015A0007) under which 13 task orders carry $923 thousand combined potential value, a Blanket Purchase Agreement (W81K0215A0026) with 12 task orders valued at $328 thousand, an Indefinite Delivery Contract (W91YU009A0004) with 10 task orders at $330 thousand, an Indefinite Delivery Contract (W81K0218D0012) with 9 task orders at $5.5 million, and a Blanket Purchase Agreement (W91YU010A0008) with 8 task orders at $622 thousand. These vehicles are predominantly Army vehicles issued to support blood testing and product supply at military medical facilities.

Activity has grown from 7 awards in 2022 to 21 in 2024, then moderated to 16 in 2025 and 9 year-to-date in 2026. Nine awards with combined potential value $13 million reach ultimate completion in the next twenty-four months, representing recompete exposure for the vendor and recompete opportunity for competitors. SCI-reported invoiced revenue across prime contracts totaled $9.8 million over FY2022–FY2025, with peak activity in FY2024 at $4.9 million across 15.7 FTEs. Government-paid hourly rates on SCI-reportable service contracts ranged from a 10th percentile of $52.68/hr to a median of $150.11/hr and a 90th percentile of $275.11/hr, reflecting a mix of laboratory technician and clinical specialist labor. Bloodworks self-performed all labor on SCI-reportable contracts with zero subcontractor hours reported, consistent with the vendor's direct-delivery model for blood products and testing services.

In its sub-recipient role on NIH research grants, Bloodworks participates in projects with University of Washington, Mayo Clinic, the University of Maryland Baltimore, and the University of Texas Health Science Center at Houston on hematology and hemostasis research funded through the National Heart, Lung, and Blood Institute and the National Institute of General Medical Sciences. Representative prime grant work includes a $724,351 Project Grant (CFDA 93.837, Cardiovascular Diseases Research) from NHLBI awarded July 1, 2026, to investigate extracellular mitochondria and endotheliopathy after traumatic brain injury (performance through April 30, 2030), and an R35 Outstanding Investigator Award from NHLBI (March 1, 2025, through February 28, 2032) for molecular and translational studies in hematologic disorders including von Willebrand disease and sickle cell disease. Bloodworks has also received grants from the National Institute of General Medical Sciences for research on platelet-CD8+ T cell interactions in sepsis (August 15, 2025, through July 31, 2030). The vendor functions as both a direct researcher and a research-support entity, performing in vitro experiments, laboratory assays on patient samples, and specialized testing panels under these agreements while maintaining its operational role as a blood bank and testing laboratory serving federal healthcare systems.